List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
16 March 2016 | By Victoria White
Researchers from NIST have shown that high-throughput screening can dramatically speed up the challenging task of antimicrobial discovery...
8 March 2016 | By Victoria White
Turning off BCL-XL with BH3-mimetic drugs killed Legionella-infected cells, allowing the infection to be cleared from the body...
3 March 2016 | By Victoria White
Scientists at the University of Brighton have shown that bacteriophage can treat infections caused by Proteus mirabilis and prevent catheter blockage...
22 February 2016 | By Katie Sadler
Pherecydes Pharma has announced the appointment of Guy-Charles Fanneau de La Horie, MBA as its new Chief Executive Officer.
Bacterial resistance to antibiotics is on the rise and a return to the ‘pre-antibiotic’ era has become a frightening possibility. Various factors are responsible for this situation: the overuse of antibiotics in human medicine and animal husbandry, insufficient public funding for research into fundamental bacteriology including resistance mechanisms, and a…
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
12 February 2016 | By Victoria White
The latest report from the Review on Antimicrobial Resistance says that vaccines and other alternatives can play a vital role in tackling the rise of drug-resistant infections...
Antibody-based targeting of vascular endothelial growth factor (VEGF) is a highly successful and widely-used clinical treatment for angiogenesis-related diseases. Currently, bevacizumab (Avastin; Genentech) and ranibizumab (Lucentis; Genentech/Roche) are the leading antibody drugs for targeting VEGF...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
13 January 2016 | By Victoria White
NIAID has awarded $5 million in funding for 24 research projects to help address the growing health threat of antibiotic resistance...
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
14 December 2015 | By Victoria White
A new study outlines a way of using antibiotic resistance to find chemicals capable of stopping amyloid formation in amyloid diseases such as Parkinson’s, Alzheimer’s and type II diabetes...
11 December 2015 | By Victoria White
The study will look at the safety and tolerability of PnuBioVax for three different dosages against the bacterial pathogen Streptococcus pneumoniae...
